Martin Shkreli is the managing member of MSMB Capital, a New York-based hedge-fund and private-equity firm focused on health care. He is also president and founder of Retrophin, a biotechnology company that develops treatments for rare and severe diseases. Shkreli has spent his career in the hedge-fund industry, previously in roles with Intrepid Capital Management and Cramer Berkowitz & Co. Shkreli lives in New York City and received a BBA in finance from Baruch College.
Recent Articles By The Author
Oncothyreon: A Failed Drug Autopsy Performed By A Short Seller
Fund manager Martin Shkreli offers advice on how to avoid the next Oncothyreon blowup.
Nektar Therapeutics Is a Short
Investor Martin Shkreli believes Nektar's constipation drug is a bust and the stock is a good short.